<SEC-DOCUMENT>0001213900-25-072827.txt : 20250807
<SEC-HEADER>0001213900-25-072827.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807081501
ACCESSION NUMBER:		0001213900-25-072827
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250807
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		251191764

	BUSINESS ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0252146-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; text-align: center; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of <B>August 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 002-023311</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2025, Ascentage
Pharma Group International issued a press release entitled, &ldquo;Ascentage Pharma to Report 2025 Six Month Interim Results and Provide
Corporate Update on August 20, 2025&rdquo;. A copy of the press release is furnished as Exhibit 99.1 to this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding: 0pt; vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; font-size: 10pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: bottom; width: 1%; font-size: 10pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; font-size: 10pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; vertical-align: top; font-size: 10pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: bottom; font-size: 10pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; vertical-align: top; text-indent: 0pt"><A HREF="ea025214601ex99-1_ascentage.htm">Press Release dated August 7, 2025 &nbsp;</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; width: 60%; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; width: 40%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 7, 2025</FONT></TD>
    <TD STYLE="padding: 0pt; border-bottom: black 1.5pt solid; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025214601ex99-1_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 7, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hong Kong Exchanges and Clearing Limited and
The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its
accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole
or any part of the contents of this announcement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>


<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Ascentage Pharma to Report 2025 Six Month Interim Results and
Provide Corporate Update on August 20, 2025</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your publication date and time will appear here.| Source:ASCENTAGE
PHARMA GROUP INTERNATIONAL</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) --
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;<B>Ascentage Pharma</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six
months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am
Hong Kong Time (HKT) on August 21, 2025.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Analysts and investors are invited to join the investor webcast with
Q&amp;A, conducted by the Company&rsquo;s management team.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma will host a Chinese (Mandarin) language investor webcast
at 9:00 pm EDT on August 20, 2025 / 9:00 am HKT on August 21, 2025.&nbsp;&nbsp;<B>To access the Chinese language investor event or conference
call, please register in advance</B>&nbsp;<B>here</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The English language investor webcast will be held at 8:00 am EDT /
8:00 pm HKT on August 21, 2025.&nbsp;<B>To access the English language webcast, please register in advance</B>&nbsp;<B>here</B>. The webcast
replay for English language presentation will also be available on the&nbsp;News &amp; Events&nbsp;page of the Ascentage Pharma website.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Ascentage Pharma Group International</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;<B>Ascentage
Pharma</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) is a global, commercial stage, integrated biopharmaceutical company engaged in
the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company
has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic
pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s first approved product, Olverembatinib, is the
first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with
T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation
TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational
Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed
Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s second approved product, Lisaftoclax, is a novel
Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China&rsquo;s National Medical
Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
who have previously received at least one systemic therapy including Bruton&rsquo;s tyrosine kinase (BTK) inhibitors. The Company is currently
conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors
in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in
patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the GLORA-4 study
in patients with newly diagnosed higher risk MDS.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leveraging its robust R&amp;D capabilities, Ascentage Pharma has built
a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading
biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development
relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the
University of Michigan. For more information, visit https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Hogan Wan, Head of IR and Strategy<BR>
Ascentage Pharma<BR>
Hogan.Wan@ascentage.com<BR>
+86 512 85557777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephanie Carrington<BR>
ICR Healthcare<BR>
AscentageIR@icrhealthcare.com<BR>
+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Jon Yu<BR>
ICR Healthcare<BR>
AscentagePR@icrhealthcare.com<BR>
+1 (646) 677-1855</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !0 /P# 2(  A$! Q$!_\0
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M7=:W!!'%>7_AV72+36K?3K^=5\RZM]-U&TGN=,CF=UL7U356MUC.H71D[/\
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MC+_DKO[-O_9//&W_ *D6D5^G/_!!S_DP71?^RI?$?_TOLJ_2'XP_LN_L]?M
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MI=K\1634-$EGB$DNGZJU]H-GILEY:,?)N'T?4-6L6D5C;7MQ$%D;]#?V%?\
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MVW[3O_!-+X4>)]7C<+J6M0?![XE? 'QKJ=SNW2W&NZAH!CM)[YV!R\6A605
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M\5_IYO$U1["[M!/=P?87P;^%W_!5OXG!;7X3_L^_LR_\$ZO!.H)]GN_&UAX
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%%/</_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
